Research Paper Volume 16, Issue 10 pp 8998—9022
Breast cancer clinical outcomes and tumor immune microenvironment: cross-dialogue of multiple epigenetic modification profiles
Figure 10. The comparison of IC50 value of anti-tumor drugs in high- and low-risk group.